An Early Phase 1 interventional study of Eligible patients' paper-based reminder in Colorectal Cancer, sponsored by Paris 12 Val de Marne University. Completed at 1 site in France. Open to participants aged 50 Years to 74 Years. Per ClinicalTrials.gov, last updated 2016-08-19.
Sponsored by Paris 12 Val de Marne University · Early Phase 1, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 583 studies in Colorectal Neoplasms with a site in France — 111 open to participants now, 165 under way, 26 of them phase 3. Colorectal Neoplasms · France.
Among the 583 studies in Colorectal Neoplasms with a site in France, this one is the 9th largest by enrollment of the 464 interventional ones that give a count, is one of 22 that started in 2010, is one of 61 in phase 1, and was the 131st registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →111 of the 583 studies in Colorectal Neoplasms with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Intercommunal Creteil · Sites in France
Ages 18+
Centre Antoine Lacassagne · Sites in France
Ages 18–75
Verastem, Inc. · Sites in France, United States, Australia and 2 more countries
Ages 18+
University Hospital, Angers · Sites in France
Ages 18+ · Healthy volunteers
EMD Serono Research & Development Institute, Inc. · Sites in France, United States, Argentina and 16 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 50 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
583 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 116 · Phase 2 207 · Phase 3 97 · Phase 4 6
First in 1993; this study’s year is marked. 22 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8,140 is above the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 152 across the 464 interventional studies, 274 across the 103 observational. Of the 358 that completed or were terminated, 107 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
224 of 583 have an industry lead sponsor. The 10 most frequent:
Paris 12 Val de Marne University is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Paris 12 Val de Marne University has 1 study filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
38 of the studies in Colorectal Neoplasms with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07520578Phase 3University Hospital, CaenEFFECTIVENESS OF EARLY INFORMATION AND ENDORSMENT BY GP TO INCREASE COLONOSCOPY FOLLOW-UP AND REDUCE DELAYS IN PEOPLE WITH A POSITIVE COLORECTAL CANCER SCREENING TEST. (SUIVICOLO) | 2027-03-24 |
| NCT07116668SafeHeal IncSafeHeal Colovac Anastomosis Protection Device Evaluation Pivotal Study | 2026-12 |
| NCT07151040One-carbon Therapeutics ABPhase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors | 2026-12 |
| NCT04585750PMV Pharmaceuticals, IncThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | 2026-12-15 |
| NCT05706779Federation Francophone de Cancerologie DigestiveEncorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer | 2026-12-30 |
Add all 38 to your calendar (.ics) → With an account.
Among the 583 studies in Colorectal Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Screening for ColoRectal Cancer (CRC) is widely recommended because of compelling evidence that it reduces mortality from CRC and that it's cost-effective. In France, there is a national CRC screening programme inviting people aged 50-74 years by mail to consult their General Practitioner (GP) for a free on charge Faecal Occult Blood test deliverance every two years. Participation is a key factor for the screening programs success. High levels of screening uptake and the continued participation to regular screening must be achieved and maintained in the targeted population if the enormous potential of CRC screening is to be realised. Screening rates of various international programs vary widely (20-52%) and the participation is insufficient in the most settings. Therefore, a better understanding of facilitating and hindering factors of patient participation can guide interventions to improve CRC screening rates. They include patients and physicians' factors. One issue is about GPs practice. GP involvement has been shown to improve the participation in the CRC screening. This study aims to assess the effectiveness of an intervention targeting GPs to increase patient participation in the CRC screening. Volunteer GPs will be randomly assigned to either the intervention group or to usual care (control group) and they will be followed one year. The intervention consists in providing every four months to the experimental group a list of their patients who are eligible but did not proceed yet to the screening. In both groups, patient participation in the screening will be measured at the end of the study.
General Practitioner (GP)
Patient
Exclusion Criteria:
Other: Eligible patients' paper-based reminder
Providing to the general practitioners every four months a list of their patients who are eligible for colorectal cancer screening but did not proceed yet and were not excluded for medical reason
Patient's participation to colorectal cancer screening program
Patient's status with colorectal cancer screening program to 15th june 2011 with two modalities 1. Update: completion of Faecal Occult Blood test or exclusion for medical reason within the duration of the study (The medical exclusions of the program are a personal or family history of Colorectal cancer, Crohn's disease, hemorrhagic rectocolitis, or hereditary nonpolyposis colorectal cancer, a colonoscopy undergone in the 5 previous years or a Fecal Occult Blood test undergone in the 2 previous years) 2. Not update
Time frame: 1 year
The record gives a start of Jun 2010, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Paris 12 Val de Marne University